MEDConsumer Cyclical · Personal ServicesThe 1 Wall Street analysts covering Medifast, Inc. hold a median 12-month price target of $12 — +5.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 8 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Medifast, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (7): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MED, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +5.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Feb 2026 | Stephens & Co. | Maintains | Equal-Weight | $15 → $12 |
| 19 Feb 2026 | Stephens & Co. | Maintains | Equal-Weight | — |
| 19 Feb 2025 | DA Davidson | Maintains | Neutral | — |
| 5 Nov 2024 | DA Davidson | Upgrade | Neutral | — |
| 22 July 2024 | DA Davidson | Maintains | Underperform | — |
| 5 June 2024 | DA Davidson | Downgrade | Underperform | — |
| 30 Apr 2024 | DA Davidson | Maintains | Neutral | — |
| 21 Feb 2024 | DA Davidson | Maintains | Neutral | — |
| 13 Oct 2023 | Stephens & Co. | Initiates | Equal-Weight | — |
| 8 Aug 2023 | DA Davidson | Maintains | Neutral | — |
| 31 July 2023 | DA Davidson | Maintains | Neutral | — |
| 2 May 2023 | DA Davidson | Maintains | Neutral | — |
| 22 Feb 2023 | DA Davidson | Maintains | Neutral | — |
| 4 Nov 2022 | DA Davidson | Downgrade | Neutral | — |
| 4 Aug 2022 | DA Davidson | Maintains | Buy | — |
| 4 Aug 2022 | Jefferies | Downgrade | Hold | — |
| 2 June 2022 | DA Davidson | Maintains | Buy | — |
| 24 Feb 2022 | DA Davidson | Maintains | Buy | — |
| 8 Nov 2021 | DA Davidson | Maintains | Buy | — |
| 5 May 2021 | DA Davidson | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MED appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Medifast, Inc. returned −18.5% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 85% of US stocks
Cheaper than 82% of US stocks
Cheaper than 54% of US stocks
Higher than 9% of US stocks
Higher than 17% of US stocks
Higher than 82% of US stocks
Higher than 27% of US stocks
Higher than 21% of US stocks
Higher than 35% of US stocks
Higher than 32% of US stocks
Higher than 99% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Medifast, Inc. has a market value of $128.7M and an enterprise value of −$23.2M.
Revenue in the twelve months to 30 June 2026: $316.9M. The latest quarter shrank 27.6% year on year.
Net income over the same four quarters: −$25.6M, a −8.1% net margin.
Diluted earnings per share, trailing twelve months: $−2.33.
Free cash flow in the twelve months to 30 June 2026: $4.0M.
Medifast, Inc. spent $813K on share buybacks and $170K on dividends in the twelve months to 30 June 2026.
Trailing P/E: 531.5×; forward P/E: −41.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 57.24%, paying out 0% of earnings.
Medifast, Inc. employs 380 people — $834K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| MEDMedifast, Inc. | $128.7M | 49 |
| RGSRegis Corp. | $73.5M | 78 |
| CSVCarriage Services, Inc. | $531.3M | 31 |
| CLIKClick Holdings Ltd. | $9.3M | 3 |
| ABLVAble View Global, Inc.* | $124.1M | 18 |
| CLARClarus Corp.* | $131.3M | 91 |
| AIIORobo.ai, Inc.* | $132.1M | 13 |
* Nearest Consumer Cyclical names by size — few personal services companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Medifast, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A GlobeNewsWire item says Trilivy, described as a science-backed, coach-guided metabolic health system, identifies lean mass preservation and continued support as factors in maintaining weight-loss results.
Why it matters — The item discusses weight-loss maintenance in the metabolic health space, which may be relevant to MED watchers.
Medifast’s revenue is stabilizing as coach productivity and client retention improve, while a shrinking coach base continues to weigh on results.
Why it matters — MED watchers may track whether better retention and coach productivity can offset pressure from the declining coach base.
A GlobeNewsWire item says weight regain can occur when the conditions that contributed to weight gain were not addressed during weight loss. It describes Trilivy, a coach-guided metabolic health system, and notes five research-identified drivers related to body composition and habits.
Why it matters — The item concerns weight-management approaches, a topic relevant to Medifast, but it does not identify a direct development involving MED.
Medifast's Trilivy™ metabolic health system highlighted five frequently overlooked signs of poor metabolic health that adults can recognize before noticeable weight and energy changes occur. The announcement points to these patterns as identifiable without needing a clinical framework.
Why it matters — This item showcases Medifast's Trilivy™ metabolic health platform, underscoring the company's educational and consumer-focused positioning in metabolic health.
A GlobeNewsWire article discusses the metabolic causes of weight loss plateaus and highlights Trilivy™, whose Reset 5 & 1 Plan is designed to address metabolic dysfunction. The article notes that clients using the plan with a coach can lose up to 10 times more weight and 17 times more fat than self-directed approaches.
Why it matters — This item promotes a Medifast-related product and its coaching-driven results, which could signal continued interest in its weight-loss offerings.
The 1 Wall Street analysts covering Medifast, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Medifast, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Medifast, Inc. 49 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Medifast, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +5.0% from the last close, and Ticker Nerd's factor model ranks Medifast, Inc. 49 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Medifast, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MED are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.
Medifast, Inc. returned -18.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Medifast Inc. is a health and wellness company focused on habit-based, coach-guided lifestyle solutions for weight management and metabolic health.
The most recent item we track (GlobeNewsWire, 8 Oct 2026): "What Actually Keeps Weight Off After a Weight Loss Program". A GlobeNewsWire item says Trilivy, described as a science-backed, coach-guided metabolic health system, identifies lean mass preservation and continued support as factors in maintaining weight-loss results.
Medifast Inc. is a health and wellness company focused on habit-based, coach-guided lifestyle solutions for weight management and metabolic health. The company’s core offering centers on the OPTAVIA brand, which combines structured nutrition products, meal replacements, and coaching support to help customers build healthier daily routines. Medifast Inc. sells a range of products including shakes, bars, soups, cereals, and other nutrition items designed for convenience and consistency within its program model. Its business serves individuals seeking weight loss and long-term healthy living support, while also relying on a network of independent coaches and digital ordering channels to deliver its services. Headquartered in Baltimore, Maryland, Medifast Inc. plays a specialized role in the broader wellness market by integrating products, guidance, and behavior-change support into a single customer experience.
CEO Mr. Nicholas M. Johnson · 380 employees · United States · https://medifastinc.com
